Nanjing Sinolife United Company Limited (3332.HK)
HKD 0.58
(1.75%)
HKD 0.58
(1.75%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 75.08 Million CNY | 1419.34% |
| 2022 | 4.88 Million CNY | 126.77% |
| 2021 | -13.48 Million CNY | 18.94% |
| 2020 | -20.95 Million CNY | 85.52% |
| 2019 | -154.7 Million CNY | -39.88% |
| 2018 | -111.07 Million CNY | -510.74% |
| 2017 | 27.06 Million CNY | -78.5% |
| 2016 | 121.32 Million CNY | -30.22% |
| 2015 | 180.23 Million CNY | 35.59% |
| 2014 | 132.92 Million CNY | 38.97% |
| 2013 | 95.64 Million CNY | 24.08% |
| 2012 | 77.08 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 22 Million CNY | 44.52% |
| 2024 Q2 | 22 Million CNY | 0.0% |
| 2023 Q4 | 15.22 Million CNY | 0.0% |
| 2023 FY | - CNY | 1419.34% |
| 2023 Q1 | 16.54 Million CNY | 991.19% |
| 2023 Q2 | 16.54 Million CNY | 0.0% |
| 2023 Q3 | 15.22 Million CNY | -7.97% |
| 2022 FY | - CNY | 126.77% |
| 2022 Q3 | -1.85 Million CNY | -217.08% |
| 2022 Q2 | -585.5 Thousand CNY | 0.0% |
| 2022 Q1 | -585.5 Thousand CNY | 94.91% |
| 2022 Q4 | -1.85 Million CNY | 0.0% |
| 2021 Q4 | -11.51 Million CNY | 0.0% |
| 2021 FY | - CNY | 18.94% |
| 2021 Q3 | -11.51 Million CNY | -195.47% |
| 2021 Q2 | -3.89 Million CNY | 0.0% |
| 2021 Q1 | -3.89 Million CNY | 68.92% |
| 2020 Q3 | -12.53 Million CNY | -797.17% |
| 2020 Q4 | -12.53 Million CNY | 0.0% |
| 2020 Q2 | -1.39 Million CNY | 0.0% |
| 2020 Q1 | -1.39 Million CNY | 95.23% |
| 2020 FY | - CNY | 85.52% |
| 2019 Q4 | -29.28 Million CNY | 0.0% |
| 2019 FY | - CNY | -39.88% |
| 2019 Q1 | -20.34 Million CNY | 30.88% |
| 2019 Q2 | -20.34 Million CNY | 0.0% |
| 2019 Q3 | -29.28 Million CNY | -43.93% |
| 2018 Q4 | -29.43 Million CNY | 0.0% |
| 2018 Q3 | -29.43 Million CNY | -788.95% |
| 2018 FY | - CNY | -510.74% |
| 2018 Q2 | 4.27 Million CNY | 0.0% |
| 2018 Q1 | 4.27 Million CNY | 128.25% |
| 2017 Q2 | 28.06 Million CNY | 0.0% |
| 2017 FY | - CNY | -78.5% |
| 2017 Q1 | 28.06 Million CNY | -17.51% |
| 2017 Q4 | -15.12 Million CNY | 0.0% |
| 2017 Q3 | -15.12 Million CNY | -153.89% |
| 2016 FY | - CNY | -30.22% |
| 2016 Q2 | 26.63 Million CNY | -0.0% |
| 2016 Q1 | 26.63 Million CNY | -52.92% |
| 2016 Q4 | 34.02 Million CNY | 0.0% |
| 2016 Q3 | 34.02 Million CNY | 27.76% |
| 2015 Q4 | 56.57 Million CNY | 0.0% |
| 2015 Q2 | 31.96 Million CNY | 0.0% |
| 2015 FY | - CNY | 35.59% |
| 2015 Q1 | 31.96 Million CNY | -23.59% |
| 2015 Q3 | 56.57 Million CNY | 77.0% |
| 2014 Q1 | 23.39 Million CNY | -30.71% |
| 2014 Q4 | 41.83 Million CNY | 0.0% |
| 2014 Q2 | 23.39 Million CNY | 0.0% |
| 2014 FY | - CNY | 38.97% |
| 2014 Q3 | 41.83 Million CNY | 78.78% |
| 2013 Q3 | 33.76 Million CNY | 56.37% |
| 2013 Q4 | 33.76 Million CNY | 0.0% |
| 2013 FY | - CNY | 24.08% |
| 2013 Q1 | 21.59 Million CNY | 1.73% |
| 2013 Q2 | 21.59 Million CNY | 0.0% |
| 2012 Q3 | 21.23 Million CNY | 7.55% |
| 2012 FY | - CNY | 0.0% |
| 2012 Q2 | 19.73 Million CNY | 0.0% |
| 2012 Q1 | 19.73 Million CNY | 0.0% |
| 2012 Q4 | 21.23 Million CNY | 0.0% |
| 2011 Q4 | 19.73 Million CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Natural Beauty Bio-Technology Limited | 22.91 Million HKD | -227.706% |
| Innovative Pharmaceutical Biotech Limited | 317.74 Million HKD | 76.37% |
| China Overseas Nuoxin International Holdings Limited | 2.02 Million HKD | -3600.542% |
| Prosperous Future Holdings Limited | -19.68 Million HKD | 481.408% |
| Huasheng International Holding Limited | 19.67 Million HKD | -281.563% |
| Fourace Industries Group Holdings Limited | 61.52 Million HKD | -22.038% |
| Evergreen Products Group Limited | 140.78 Million HKD | 46.666% |
| EC Healthcare | 737.83 Million HKD | 89.824% |
| Ming Fai International Holdings Limited | 211.83 Million HKD | 64.555% |
| Blue Moon Group Holdings Limited | 656.37 Million HKD | 88.561% |
| SuperRobotics Holdings Limited | -7.39 Million HKD | 1114.786% |
| Takbo Group Holdings Limited | 25.8 Million HKD | -190.978% |
| Hyfusin Group Holdings Limited | 154.18 Million HKD | 51.303% |